BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) A
Post# of 122
(Total Views: 174)
Posted On: 08/14/2023 5:04:40 PM
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics
- Innovative nanobody therapeutics could deliver substantial competitive advantages in both cost and efficacy when compared to traditional monoclonal antibody therapies
- The biologics market was valued at $366.5 billion in 2021 and is expected to grow to a value of $719.94 billion by 2030
- The monoclonal antibodies market was valued at $210.06 billion in 2022, and it is expected to reach $494.53 billion by 2030
- The nanobody market was valued $237.1 million in 2021 and is expected reach a value of $1.07 billion by 2028
- BiondVax is uniquely positioned to rapidly advance from R&D towards commercialization
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is planning a rapid development path that leverages the company’s expertise and capabilities in biological drug development and manufacturing. Using a platform of alpaca-derived nanobodies (NanoAbs), BiondVax is targeting large market disorders underserved by current therapeutics, including COVID-19, asthma, and psoriasis. BiondVax’s diverse and growing pipeline is being developed in collaboration with the world renowned Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) in Germany.
The biologics market, which is comprised of any pharmaceutical drug product manufactured in, extracted from, or semi-synthesized from biological sources, was valued at $366.5 billion in 2021 and is expected to grow at a CAGR of 7.15%, resulting in a value of $719.94 billion by 2030. The introduction of targeted therapies and the rising adoption of patient-centric personalized medicine is anticipated to drive the market growth (https://nnw.fm/xXpyC ). The increased demand for biologics is expected to further drive the monoclonal antibodies market size, valued at $210.06 billion in 2022 and expected to reach $494.53 billion by 2030, growing at a CAGR of 11.04% (https://nnw.fm/xuuV4 ).
Leveraging its innovative NanoAb platform, BiondVax is penetrating a market with an eye-popping projected CAGR of 24.1% and quadrupling in value to $1.07 billion in five years. (https://nnw.fm/Xq25A ). NanoAbs offer significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production – BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.
BiondVax’s pipeline development remains the company’s core focus. In addition, it recently announced expanding its offering of services as a boutique end-to-end contract development and manufacturing organization (“CDMO”). The CDMO services allow BiondVax to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services. The new service offering allows the company to use its proven experience running pre-clinical trials, clinical trials, chemistry, manufacturing, and more to accelerate development of their clients’ products.
“Offering CDMO services allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” BiondVax CEO Amir Reichman said in a recent interview (https://nnw.fm/xHGsO ).
The company has shown incredible initial results and enormous promise with its innovative Covid-19 treatment. It has built a state-of-the-art biopharmaceutical product manufacturing facility that houses laboratories, production facilities, and offices. The BiondVax team also includes highly experienced and successful pharmaceutical industry leaders, including former senior executives from Novartis, GSK, and Bristol-Myers Squibb.
With the rising adoption of biopharmaceuticals over chemically synthesized molecules, the biologics market (which encompasses monoclonal antibodies and nanobodies) is expected to grow significantly and propel revenue potential. BiondVax is positioned to disrupt the market with its innovative and potentially block buster NanoAb therapeutics.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Innovative nanobody therapeutics could deliver substantial competitive advantages in both cost and efficacy when compared to traditional monoclonal antibody therapies
- The biologics market was valued at $366.5 billion in 2021 and is expected to grow to a value of $719.94 billion by 2030
- The monoclonal antibodies market was valued at $210.06 billion in 2022, and it is expected to reach $494.53 billion by 2030
- The nanobody market was valued $237.1 million in 2021 and is expected reach a value of $1.07 billion by 2028
- BiondVax is uniquely positioned to rapidly advance from R&D towards commercialization
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is planning a rapid development path that leverages the company’s expertise and capabilities in biological drug development and manufacturing. Using a platform of alpaca-derived nanobodies (NanoAbs), BiondVax is targeting large market disorders underserved by current therapeutics, including COVID-19, asthma, and psoriasis. BiondVax’s diverse and growing pipeline is being developed in collaboration with the world renowned Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) in Germany.
The biologics market, which is comprised of any pharmaceutical drug product manufactured in, extracted from, or semi-synthesized from biological sources, was valued at $366.5 billion in 2021 and is expected to grow at a CAGR of 7.15%, resulting in a value of $719.94 billion by 2030. The introduction of targeted therapies and the rising adoption of patient-centric personalized medicine is anticipated to drive the market growth (https://nnw.fm/xXpyC ). The increased demand for biologics is expected to further drive the monoclonal antibodies market size, valued at $210.06 billion in 2022 and expected to reach $494.53 billion by 2030, growing at a CAGR of 11.04% (https://nnw.fm/xuuV4 ).
Leveraging its innovative NanoAb platform, BiondVax is penetrating a market with an eye-popping projected CAGR of 24.1% and quadrupling in value to $1.07 billion in five years. (https://nnw.fm/Xq25A ). NanoAbs offer significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production – BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.
BiondVax’s pipeline development remains the company’s core focus. In addition, it recently announced expanding its offering of services as a boutique end-to-end contract development and manufacturing organization (“CDMO”). The CDMO services allow BiondVax to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services. The new service offering allows the company to use its proven experience running pre-clinical trials, clinical trials, chemistry, manufacturing, and more to accelerate development of their clients’ products.
“Offering CDMO services allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” BiondVax CEO Amir Reichman said in a recent interview (https://nnw.fm/xHGsO ).
The company has shown incredible initial results and enormous promise with its innovative Covid-19 treatment. It has built a state-of-the-art biopharmaceutical product manufacturing facility that houses laboratories, production facilities, and offices. The BiondVax team also includes highly experienced and successful pharmaceutical industry leaders, including former senior executives from Novartis, GSK, and Bristol-Myers Squibb.
With the rising adoption of biopharmaceuticals over chemically synthesized molecules, the biologics market (which encompasses monoclonal antibodies and nanobodies) is expected to grow significantly and propel revenue potential. BiondVax is positioned to disrupt the market with its innovative and potentially block buster NanoAb therapeutics.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)